Study Confirms COVID-19 Vaccine Heart Protection Persists in Updated Shots

An extensive VA analysis of over 1 million veterans shows the 2024‑2025 formulation still delivers COVID-19 vaccine heart protection.

COVID-19 vaccine heart protection remains robust in seniors

Researchers tracked major adverse cardiovascular events – death, heart attack, stroke, heart‑failure admission – and found a ↑ 12% reduction versus unvaccinated peers. The benefit was most pronounced in patients older than 75 and those with pre‑existing conditions. The study, published in JAMA Internal Medicine, aligns with earlier data linking vaccination to lower cardiac risk during infection. As the virus mutates and population immunity evolves, the protective signal endures, a point highlighted by

“the vaccine’s cardiovascular shield appears resilient,” said a senior VA epidemiologist.

For broader context, see recent coverage by Reuters and Bloomberg. The findings also intersect with ongoing debates about the pandemic response and long‑term health strategy.